Evidence map›Paper›PMID 19389060›Full record

SynthesisObesity reviews : an official journal of the International Association for the Study of Obesity2009

Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis.

A N Fabricatore, T A Wadden, R H Moore, M L Butryn, E A Gravallese, N E Erondu, S B Heymsfield, A M Nguyen

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Obesity reviews : an official journal of the International Association for the Study of Obesity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A N FabricatoreCenter for Weight and Eating Disorders, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA. fabricat@mail.med.upenn.edu
T A Wadden
R H Moore
M L Butryn
E A Gravallese
N E Erondu
S B Heymsfield
A M Nguyen

Funding

IMPROVING THE EFFECTIVENESS OF OBESITY MANAGEMENTK24DK065018 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI WADDEN, THOMAS A. · 2003 to 2013
$1.4M
A trial of two diets for weight and diabetes managementK23DK070777 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI FABRICATORE, ANTHONY N · 2005 to 2009
$615k
NIDDK NIH HHS K23 DK070777NIDDK NIH HHS K24 DK065018
6 · The paper itself

Abstract

Clinical trials of obesity treatments have been limited by substantial dropout. Participant-level variables do not reliably predict attrition, and study-level variables have not yet been examined. We searched MEDLINE and identified 24 large randomized controlled trials of weight loss medications. These trials were comprised of 23 placebo and 32 drug groups. Two authors independently extracted the following for each treatment group: (i) treatment received; (ii) design characteristics (inclusion of a lead-in period, selection of participants with weight-related comorbidities, study location and number of study visits); (iii) sample characteristics (sample size, % female, and mean baseline age and body mass index); and (iv) attrition (total, adverse event [AE]-related and non-AE-related) at 1 year. The primary outcome was total attrition, which was significantly related to treatment (i.e. 34.9%, 28.6%, 28.3% and 35.1% in placebo, orlistat, sibutramine and rimonabant groups, respectively, P < 0.0001). In adjusted multivariable models, total attrition was significantly lower in groups that completed a pre-randomization lead-in period than in those that did not (29.1% vs. 39.9%, P < 0.01). Gender also was significantly related to total attrition; groups with more women had higher dropout (P < 0.01). The pattern was similar for predicting non-AE-related attrition. Findings suggest ways to design studies that maximize retention.

Indexed as

Anti-Obesity AgentsHumansMultivariate AnalysisPatient DropoutsRandomized Controlled Trials as TopicResearch DesignAnti-Obesity Agents

Identifiers

PMID19389060
PMCPMC2682632

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.